Analysts: Genomic Solutions Pays $5.5 Million in PerkinElmer Settlement But May Get Back More | GenomeWeb

NEW YORK, April 19 – In settling a suit with PerkinElmer Thursday, Genomic Solutions has paid PerkinElmer $5.5 million to buy back a large part of its stock, and given UK distribution rights to its products to PerkinElmer, but the settlement may make the company more attractive to investors, analysts are saying.

The settlement terminates PerkinElmer’s “call right” to shares of Genomic Solutions stock, which allowed PerkinElmer to call in all shares of Genomic Solutions and become the sole shareholder.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.